Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2014—Biocartis announced the launch of its flagship molecular diagnostics system, Idylla. With Idylla, Biocartis also released its first oncology assay, the Idylla BRAF Mutation Test. Both Idylla and the Idylla BRAF Mutation Test have obtained CE-IVD marking.
November 2014—Ventana Medical Systems announced that its Ventana System for Primary Diagnosis has been CE marked in the European Union for routine pathology, including for primary diagnosis with human tissue specimens.
October 2014—Neoteryx announced the launch of the Mitra (RUO) Microsampling Device for the collection, transport, storage, and analysis of biological fluids. In seconds, the research-use-only Mitra microsampler consistently collects 10 µL of fluid while eliminating the volumetric blood hematocrit bias typically associated with the dried blood spotting technique.
October 2014—AstraZeneca announced it has entered into a collaboration with Roche to develop a plasma-based companion diagnostic test to support AZD9291, AstraZeneca’s investigational compound in clinical development for non-small cell lung cancer.
October 2014—Enzo Life Sciences now offers the Amp’d GLP-1 ELISA Kit, a rapid ELISA for the detection of the active form of glucagon-like peptide 1. The kit can be used to quantify the active form of human GLP-1 in serum and plasma samples.
October 2014—Viewics released its Utilization Management solution specifically designed for laboratories. The Viewics solution enables laboratories and pathology groups to leverage massive amounts of data into customized dashboards, analyses, and insights that drive successful utilization management initiatives.
October 2014—The Cells-to-CT 1-Step Power SYBR Green Kit from Life Technologies makes it possible to perform expression analysis directly from cultured cells without RNA purification. This new addition includes cell lysis reagents with gDNA removal and the Power SYBR Green 1-Step RT-PCR master mix.
October 2014—The Viaflo Assist is a multichannel pipette from Integra that works with Viaflo II electronic pipettes to prevent users from repetitive strain injuries and to significantly increase the reproducibility of prolonged pipetting protocols such as serial dilutions, plate fillings, and reagent addition.
October 2014—Illumina announced it has formed collaborative partnerships with leading pharmaceutical companies to develop a universal next-generation-sequencing-based oncology test system.
October 2014—The bioT3 Metastatic Cancer Solution from BioTheranostics now includes a single assay that covers genetic mutations and protein expression.
